Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice

Table 2 CD4 ⁺ _, CD8 ⁺ subtypes of T cells from immunized mice were measured using flow cytometry

Immunization route^a	Immunization regimen	CD4⁺(%)^b	CD8⁺(%)^b
Intramuscular vaccination	PBS	26.71 ± 1.32	21.67 ± 0.82
	pVAX1	25.45 ± 1.13	22.37 ± 0.98
	pVAX1-MEG-CTXA₂/B	24.56 ± 1.25	28.54 ± 0.92
Intranasal vaccination	BRD509	25.71 ± 0.64	22.37 ± 0.83
	BRD509/pVAX1	24.32 ± 1.75	26.34 ± 0.93
	BRD509/pVAX1-MEG-CTXA₂/B	24.68 ± 1.43	30.01 ± 1.78
Intraoral vaccination	BRD509	27.45 ± 1.91	24.38 ± 0.98
	BRD509/pVAX1	24.32 ± 1.21	30.28 ± 0.53
	BRD509/pVAX1-MEG-CTXA₂/B	25.15 ± 1.55	35.55 ± 0.70

^aMice were immunized by three immunization routes, intramuscular, intraoral, intranasal, on day 0 and day 14 and day 28 with different immunization regimens.
^bThe splenocyte culture supernatants taken from mice (n = 3, each group) 2 weeks after the last immunization were stained with FITC-labeled anti-mouse CD8⁺ monoclonal antibody and PE-labeled anti-mouse CD4⁺ monoclonal antibody, T lymphocyte subsets were measured using flow cytometry.

ISSN: 1756-3305